Effects of enzymatically inactive recombinant botulinum neurotoxin type A at the mouse neuromuscular junctions

Toxicon

Volumn 72, Issue , 2013, Pages 71-80

  Baskaran, Padmamalini ^a   Lehmann, Teresa E ^b   Topchiy, Elena ^b   Thirunavukkarasu, Nagarajan ^c   Cai, Shuowei ^c   Singh, Bal Ram ^c   Deshpande, Sharad ^a   Thyagarajan, Baskaran ^a  

^a UNIVERSITY OF WYOMING COLLEGE OF HEALTH SCIENCES   (United States)

^b UNIVERSITY OF WYOMING   (United States)

^c UNIVERSITY OF MASSACHUSETTS DARTMOUTH   (United States)

Author keywords

Acetylcholine release; Deactivated; Nerve muscle preparation; Neuromuscular junction; Non toxic botulinum neurotoxin A; Recombinant botulinum neurotoxin A

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; DEACTIVATED RECOMBINANT BOTULINUM NEUROTOXIN A; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG UPTAKE; IN VITRO STUDY; MOUSE; NERVE ENDING; NEUROMUSCULAR SYNAPSE; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN HYDROLYSIS; REFLEX; TOXICITY TESTING;

ACETYLCHOLINE; ACETYLCHOLINE RELEASE; ACH; BONT/A; BOTULINUM NEUROTOXIN A; DEACTIVATED; DEACTIVATED RECOMBINANT BONT/A; DRBONT/A; EDL; ENDPLATE CURRENT; EPC; EXTENSOR DIGITORUM LONGUS; HC; HEAVY CHAIN; HEPES RINGER SOLUTION; HRS; LC; LIGHT CHAIN; MEPC; MINIATURE EPC; MNT; MOTOR NERVE TERMINALS; NERVE MUSCLE PREPARATION; NERVE MUSCLE PREPARATIONS; NEUROMUSCULAR JUNCTION; NMPS; NON-TOXIC BOTULINUM NEUROTOXIN A; RECOMBINANT BOTULINUM NEUROTOXIN A; TOE SPREAD REFLEX; TSR;

ACETYLCHOLINE; ANIMALS; BOTULINUM TOXINS, TYPE A; HALF-LIFE; MICE; MICE, INBRED C57BL; MUSCLES; NEUROMUSCULAR JUNCTION; RECOMBINANT PROTEINS;

EID: 84880400581     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2013.06.014     Document Type: Article

References (38)

1. Adler M., Deshpande S.S., Apland J.P., Murray B., Borrell A. Reversal of BoNT/A-mediated inhibition of muscle paralysis by 3,4-diaminopyridine and roscovitine in mouse phrenic nerve-hemidiaphragm preparations. Neurochem. Int. 2012.
2. Apostolidis A. Treatment of overactive bladder with botulinum toxin: are there more challenges to deal with?. Eur. Urol. 2012, 62:515-517.
3. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Fine A.D., Hauer J., Layton M., Lillibridge S., Osterholm M.T., O'Toole T., Parker G., Perl T.M., Russell P.K., Swerdlow D.L., Tonat K. Botulinum toxin as a biological weapon: medical and public health management. Jama 2001, 285:1059-1070.
4. Benedetto A.V. The cosmetic uses of botulinum toxin type A. Int. J. Dermatol. 1999, 38:641-655.
5. Binz T., Sikorra S., Mahrhold S. Clostridial neurotoxins: mechanism of SNARE cleavage and outlook on potential substrate specificity reengineering. Toxins (Basel) 2010, 2:665-682.
6. Brunger A.T., Rummel A. Receptor and substrate interactions of clostridial neurotoxins. Toxicon 2009, 54:550-560.
7. Cai S., Kukreja R., Shoesmith S., Chang T.W., Singh B.R. Botulinum neurotoxin light chain refolds at endosomal pH for its translocation. Protein J. 2006, 25:455-462.
8. Chertow D.S., Tan E.T., Maslanka S.E., Schulte J., Bresnitz E.A., Weisman R.S., Bernstein J., Marcus S.M., Kumar S., Malecki J., Sobel J., Braden C.R. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. Jama 2006, 296:2476-2479.
9. Dolly J.O., Wang J., Zurawski T.H., Meng J. Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators. FEBS J. 2011, 278:4454-4466.
10. Dong M., Liu H., Tepp W.H., Johnson E.A., Janz R., Chapman E.R. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol. Biol. Cell 2008, 19:5226-5237.
11. Fabbri A., Travaglione S., Falzano L., Fiorentini C. Bacterial protein toxins: current and potential clinical use. Curr. Med. Chem. 2008, 15:1116-1125.
12. Foran P.G., Mohammed N., Lisk G.O., Nagwaney S., Lawrence G.W., Johnson E., Smith L., Aoki K.R., Dolly J.O. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J. Biol. Chem. 2003, 278:1363-1371.
13. Fu Z., Chen S., Baldwin M.R., Boldt G.E., Crawford A., Janda K.D., Barbieri J.T., Kim J.J. Light chain of botulinum neurotoxin serotype A: structural resolution of a catalytic intermediate. Biochemistry 2006, 45:8903-8911.
14. Gautron J. Ultrastructural localization of acetylcholinesterase. A direct method for light and electron microscopy. Histochemistry 1982, 76:469-478.
15. Gutmann E., Gutmann L., Medawar P.B., Young J.Z. The rate of regeneration of nerve. J. Exp. Biol. 1942, 19:14-44.
16. Jabbari B., Machado D. Treatment of refractory pain with botulinum toxins-an evidence-based review. Pain Med. 2011, 12:1594-1606.
17. 2, a major active component in the thiolacetic acid histochemical method for acetylcholinesterase. J. Histochem. Cytochem. 1968, 16:743-753.
18. Kukreja R.V., Sharma S., Cai S., Singh B.R. Role of two active site Glu residues in the molecular action of botulinum neurotoxin endopeptidase. Biochim. Biophys. Acta 2007, 1774:213-222.
19. Lacy D.B., Stevens R.C. Unraveling the structures and modes of action of bacterial toxins. Curr. Opin. Struct. Biol. 1998, 8(6):778-784.
20. Li D., Mattoo P., Keller J.E. New equine antitoxins to botulinum neurotoxins serotypes A and B. Biologicals 2012, 40:240-246.
21. Li L., Binz T., Niemann H., Singh B.R. Probing the mechanistic role of glutamate residue in the zinc-binding motif of type A botulinum neurotoxin light chain. Biochemistry 2000, 39:2399-2405.
22. Li L., Singh B.R. Role of zinc binding in type A botulinum neurotoxin light chain's toxic structure. Biochemistry 2000, 39:10581-10586.
23. Montal M. Translocation of botulinum neurotoxin light chain protease by the heavy chain protein-conducting channel. Toxicon 2009, 54:565-569.
24. Montecucco C., Schiavo G. Mechanism of action of tetanus and botulinum neurotoxins. Mol. Microbiol. 1994, 13:1-8.
25. Nurmikko T., Cruccu G. Botulinum toxin for trigeminal neuralgia. Eur. J. Neurol. 2009, 16:e104.
26. Pickett A., Perrow K. Towards new uses of botulinum toxin as a novel therapeutic tool. Toxins 2011, 3:63-81.
27. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80:717-766.
28. Simpson L.L. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 2004, 44:167-193.
29. Singh B.R., Thirunavukkarasu N., Ghosal K., Ravichandran E., Kukreja R., Cai S., Zhang P., Ray R., Ray P. Clostridial neurotoxins as a drug delivery vehicle targeting nervous system. Biochimie 2010, 92:1252-1259.
30. Sobel J., Dill T., Kirkpatrick C.L., Riek L., Luedtke P., Damrow T.A. Clinical recovery and circulating botulinum toxin type F in adult patient. Emerg. Infect. Dis. 2009, 15:969-971.
31. Souayah N., Karim H., Kamin S.S., McArdle J., Marcus S. Severe botulism after focal injection of botulinum toxin. Neurology 2006, 67:1855-1856.
32. Thirunavukkarasu N, Singh B.R. Structure and trafficking potentials of botulinum neurotoxin in drug delivery. Botulinum J. 2010, 1:349-357.
33. Thyagarajan B., Krivitskaya N., Potian J.G., Hognason K., Garcia C.C., McArdle J.J. Capsaicin protects mouse neuromuscular junctions from the neuroparalytic effects of botulinum neurotoxin a. J. Pharmacol. Exp. Ther. 2009, 331:361-371.
34. Thyagarajan B., Potian J.G., Garcia C.C., Hognason K., Capkova K., Moe S.T., Jacobson A.R., Janda K.D., McArdle J.J. Effects of hydroxamate metalloendoprotease inhibitors on botulinum neurotoxin A poisoned mouse neuromuscular junctions. Neuropharmacology 2010, 58:1189-1198.
35. Verderio C., Rossetto O., Grumelli C., Frassoni C., Montecucco C., Matteoli M. Entering neurons: botulinum toxins and synaptic vesicle recycling. EMBO Rep. 2006, 7:995-999.
36. Wang J., Zurawski T.H., Meng J., Lawrence G.W., Aoki K.R., Wheeler L., Dolly J.O. Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis. FASEB J. 2012.
37. Weiping Yang P.L., Riding Stephen, Chang Tzuu-Wang, Cai Shuowei, Van Thuan, Kukreja Roshan, Zhou Yu, Vasa Kruti, Singh Bal Ram Expression, purification and comparative characterisation of enzymatically deactivated recombinant botulinum neurotoxin type A. Botulinum J. 2008, 1:219.
38. Yuan R.Y., Sheu J.J., Yu J.M., Chen W.T., Tseng I.J., Chang H.H., Hu C.J. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009, 72:1473-1478.